Good Doctor · Hyperthermic Perfusion | Literature Brief Review | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Metastasis: Current Status and Future Prospects
According to reports from 2020, there were 1.09 million new cases of gastric cancer worldwide, making it the fifth most common cancer; deaths from gastric cancer totaled 770,000, ranking it fourth. In China, more than 500,000 cancer patients have peritoneal metastases from gastric cancer.
2026-08-21
According to 2020 literature, the global incidence of gastric cancer reached 1.09 million cases, ranking fifth among all newly diagnosed cancers; mortality stood at 770,000, placing it fourth [1, 2]. In China, more than 500,000 cancer patients have peritoneal metastases from gastric cancer [3]. Approximately 20% of gastric cancer patients are found to have peritoneal metastases preoperatively or intraoperatively, and most patients with advanced T3 or T4 gastric cancer develop peritoneal recurrence after curative surgery [4]. With systemic chemotherapy alone, the median survival is only 6–10 months, and long-term survival remains extremely difficult to achieve; therefore, peritoneal metastasis from gastric cancer was once considered incurable. Hyperthermic intraperitoneal chemotherapy (HIPEC), combined with cytoreductive surgery (CRS), relies on… Hyperthermia + local high-concentration chemotherapy + mechanical irrigation + immune modulation The fourfold synergistic effect has established this approach as a core local treatment modality for such patients. Drawing on the findings of numerous randomized, controlled clinical trials from both Eastern and Western settings, we offer a brief review of the current status and future prospects of CRS plus HIPEC for treating peritoneal metastases from gastric cancer.

Figure: Schematic diagram of the process of peritoneal metastasis in gastric cancer. (A) Formation of the primary gastric tumor; (B) Alteration of the peritoneal microenvironment; (C) Direct invasion, shedding, and implantation of tumor cells; (D) Dissemination of tumor cells via the bloodstream; (E) Dissemination of tumor cells via the lymphatic system; (F) Development of peritoneal metastatic foci.
Image source: Website of the Chinese Academy of Sciences, “The Institute of Automation and Others Achieve Progress in Intelligent Diagnosis of Occult Peritoneal Metastasis in Gastric Cancer”
Past: Theoretical Foundations and Early Exploration (1980s–2015)
Establishment of the Theoretical Foundation
In the 1980s, the global consensus held that peritoneal metastases from gastric cancer represented an advanced-stage disease, amenable only to palliative chemotherapy with no curative options. Japanese researchers, including Fujimoto and Koga, were among the first to demonstrate that hyperthermia at 42–43°C could enhance the cytotoxic effects of platinum agents and mitomycin C. Moreover, due to the blood–peritoneum barrier, localized intraperitoneal administration can achieve intraperitoneal drug concentrations tens of times higher than those attained with systemic intravenous delivery; concurrent large-volume lavage effectively removes free cancer cells from the peritoneal cavity, thereby establishing the theoretical foundation for HIPEC in the treatment of peritoneal metastases from gastric cancer [5–7].
Early clinical results in Asia show preliminary benefits.
Asia has been at the forefront of clinical exploration: Early small-scale randomized controlled studies in Japan demonstrated that adjuvant hyperthermic intraperitoneal chemotherapy following curative resection can reduce peritoneal recurrence [6, 7]. In 2011, a domestic phase III randomized clinical trial led by Yang Jianping confirmed that, compared with surgery alone (CRS), CRS plus HIPEC extended median survival from 6.5 months to 11 months, providing, for the first time, high‑level evidence of the survival benefit of HIPEC [8].
A Western Beginnings, Accompanied by Controversy
Europe and the United States started later, with early studies predominantly consisting of single-center, retrospective analyses. A 2014 review noted that the guidelines of the European Society for Medical Oncology (ESMO), the National Comprehensive Cancer Network (NCCN), and the Japanese Gastric Cancer Association (JGCA) recommend CRS plus HIPEC only within clinical trials, not as a standard clinical practice. The core controversies include small sample sizes, lack of standardized protocols, absence of data from large, randomized controlled trials, significant surgical morbidity, and high rates of complications [9]. Early HIPEC regimens lacked uniformity: infusion durations were mainly 60 minutes, and drugs such as mitomycin C and cisplatin were commonly used; screening criteria were vague, and no stratification system based on the peritoneal cancer index (PCI) had been established, resulting in limited postoperative benefits for patients with high tumor burden. During this period, most studies were single-center, retrospective, and involved small cohorts, with substantial differences between Eastern and Western chemotherapy regimens—S‑1 in Asia versus ECX/FLOT in Europe and the United States—and no unified HIPEC procedural standards [9–12].
Current Status: Hierarchical Standardization and Evidence Enhancement (2016–2025)
Patient stratification criteria have been established, and percutaneous coronary intervention (PCI) has become a core screening criterion.
Multiple studies have consistently confirmed that a PCI ≤ 6 and achieving complete cytoreduction with CC0 are the critical thresholds for clinical benefit:
Domestic Phase II CLASS-05 study: Among patients with peritoneal carcinomatosis (PCI) ≤6, the median overall survival was 29 months; for those with PCI >6, it was only 11 months, a statistically significant difference [13].
Results from multicenter cohort studies in Germany and France both indicate that patients with excessively extensive PCI or those who cannot achieve complete cytoreduction are unlikely to derive clinical benefit from HIPEC; accordingly, a standardized preoperative laparoscopic assessment protocol for PCI has been established [14–17].
Breakthroughs in HIPEC Perfusion Duration and Protocol Optimization
A 2023 single-center retrospective study conducted in Germany (Steinhoff et al., including 73 cases of GC‑PM) marked a significant milestone [18]: with a 60‑minute HIPEC regimen, the median overall survival was 12.86 months, whereas the 90‑minute cisplatin perfusion group achieved 27.3 months; after propensity‑score matching, this difference remained statistically significant (HR = 0.2843, P = 0.0082), confirming that extending the thermal perfusion to 90 minutes can substantially improve disease‑specific survival. Since 2018, centers in Europe and North America have increasingly adopted 90 minutes as the preferred protocol.
Drugs have established mainstream regimens: cisplatin plus doxorubicin in Europe and the United States, and docetaxel in Asia. Meanwhile, a standardized protocol for using sodium thiosulfate to protect the kidneys from cisplatin‑induced nephrotoxicity has been implemented, thereby reducing perioperative renal toxicity.
Multimodal integrated treatment protocol: conversion therapy + HIPEC + surgery
Neoadjuvant systemic plus intraperitoneal bidirectional conversion therapy has become the mainstream approach:
A prospective cohort study from the Zhejiang Cancer Center in China [19] demonstrated that patients who underwent neoadjuvant systemic plus intraperitoneal chemotherapy to downstage the disease, followed by CRS plus HIPEC, had a median overall survival of 21.1 months, whereas those receiving palliative chemotherapy alone had a median overall survival of only 10.8 months.
2023 German GASTRIPEC Phase III randomized trial [20]: In the overall population, there was no difference in overall survival between CRS alone and CRS plus HIPEC (both 14.9 months); however, in the CC0 complete cytoreduction subgroup, the addition of HIPEC significantly prolonged distant‑metastasis–free survival, thereby clarifying that the clinical benefit of HIPEC is limited to patients who achieve complete cytoreduction and resolving the conflicting results of previous studies.
Widespread adoption and enhanced safety of minimally invasive HIPEC
The laparoscopic CRS (L‑CRS) combined with multiple, sequential postoperative HIPEC sessions (on days 1, 3, and 5 after surgery) has been well established [13, 21]. The CLASS‑05 study demonstrated that minimally invasive surgery was associated with only 20% of complications, including 10% of severe complications, and a median hospital stay of 8 days, substantially reducing the morbidity compared with conventional open surgery; this approach is particularly suitable for younger patients with localized peritoneal metastases [13].
Differences in Evidence Between East and West
The Asian multicenter prospective study was overall positive [22]; the large European and American Phase III trial (GASTRIPEC) was generally negative, yet subgroup analysis demonstrated clear benefits [23]; guidelines have been updated to recommend HIPEC selectively for patients with low PCI scores and those undergoing complete cytoreductive surgery, restricted to specialized peritoneal tumor centers, while no longer categorically dismissing its efficacy in treating peritoneal metastases from gastric cancer [24–27].
The Future: Precision, Personalization, and the Integration of New Technologies
□ Precise case selection and molecular stratification therapy
Liquid biopsy (including peritoneal free tumor cells and ctDNA) can predict peritoneal micrometastases, enabling early identification of high-risk patients who require prophylactic HIPEC following curative surgery [28–30].
Molecular subtyping–guided therapy: For HER2‑positive patients, combination treatment with trastuzumab and intraperitoneal chemotherapy has demonstrated, in retrospective analyses, improved survival; for the peritoneal‑type and signet‑ring cell carcinoma subgroups, tailored intraperitoneal drug regimens have been developed, moving away from a one‑size‑fits‑all approach [31, 32].
□ The HIPEC protocol continues to evolve.
A 90-minute perfusion extension protocol has been subjected to multicenter, randomized validation, confirming long-term survival benefits [33, 34].
Intraperitoneal targeted therapy combined with immunotherapy and hyperthermic perfusion: for example, catumaxomab is used for malignant ascites, and intraperitoneal PD‑1 inhibitors in combination with hyperthermia synergistically eradicate peritoneal micrometastases [35–38].
Pressurized intraperitoneal aerosol chemotherapy (PIPAC), as a palliative alternative for patients who are intolerant to surgery or have lost the opportunity for surgical intervention, is being evaluated in concurrent comparative studies [39–41].
□ Large-scale Phase III clinical trials provide Level I evidence.
Several global, multicenter randomized trials are underway: the European PERISCOPE II and GASTRICH studies, as well as the domestic HIPEC‑01 and HIPEC‑02 trials. These studies compare “conversion therapy plus CRS plus HIPEC” with systemic chemotherapy alone and hold the potential to revise international gastric cancer guidelines, thereby harmonizing treatment standards across Eastern and Western practices [42–44].
□ Prophylactic HIPEC is gaining attention
For high-risk gastric cancer with T3/T4 serosal invasion and positive peritoneal cytology (without macroscopic peritoneal metastases), prophylactic HIPEC reduces postoperative peritoneal recurrence. The German PREVENT Phase III FLOT plus prophylactic HIPEC study is currently enrolling patients and holds the potential to expand the indications for HIPEC from advanced metastatic disease to locally advanced, resectable gastric cancer [45–47].
□ Minimally Invasive and Intelligent Treatment
The CRS robot, combined with intraoperative real-time temperature monitoring and uniform perfusion systems, ensures stable intraperitoneal drug temperatures. Meanwhile, artificial intelligence constructs a prognostic model based on PCI, complete blood counts, and tumor markers, enabling precise prediction of whether patients will benefit from HIPEC and thereby avoiding unnecessary surgery and the associated trauma caused by ineffective perfusion [48–52].
In the past, peritoneal metastases from gastric cancer were considered incurable, and HIPEC for this indication remained highly controversial. Today, standardized approaches have emerged, including stratified patient selection, prolonged 90‑minute perfusion, and a comprehensive multimodal strategy combining CRS with HIPEC. Patients with low PCI scores and complete cytoreduction (CC0) can achieve a doubled median survival. Looking ahead, the field is poised to move toward… Molecular precision stratification, immuno‑targeted combination therapy, prophylactic application, and minimally invasive intelligent technologies. Through large-scale randomized trials, global treatment guidelines have been standardized, fundamentally challenging the longstanding perception that peritoneal metastases from gastric cancer are incurable; however, this therapy still requires multidisciplinary team (MDT) collaboration and must be administered at centers with specialized expertise in peritoneal malignancies, with meticulous adherence to surgical debulking protocols and rigorous patient selection criteria.
Expert Profile

Dr. Liu, M.D., Ph.D.
Professional Society Member
American Society for Cell Biology (2006–present)
American Heart Association (2006–present)
American Thoracic Society (1997–present)
2023–2025.5 Associate Professor, Department of Cardiology, University of Miami, USA
1999–2023 Assistant/Associate Professor, Division of Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, USA
1996–1999 Postdoctoral Fellow, Department of Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, USA
1992–1995: Master of Medicine, Department of Respiratory Medicine, Xijing Hospital, Fourth Military Medical University (under Professor Sun Bin)
1986–1992: Clinical Physician, Department of Respiratory Medicine, General Hospital of the Shenyang Military Region
1981–1986 Bachelor of Medicine, Department of Clinical Medicine, Fourth Military Medical University
References
1. Yang, W-J., et al. Updates on global epidemiology, risk and
prognostic factors of gastric cancer.World J.Gastroenterol.2023;29(16):
2452
2. Sung, H., et al. Global cancer statistics 2020: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in 185
countries.Cancer J.Clin.2021;71(3),209–249
3. Yang R, Su Y, Ma R, Li Y. Clinical epidemiology of peritoneal metastasis in China: the construction of professional peritoneal metastases treatment centers based on the prevalence rate. Eur J Surg Oncol. 2023;49:173-8.
4. Ikoma N, Chen HC, et al. Patterns of initial recurrence in gastric adenocarcinoma in the era of preoperative therapy. Ann Surg Oncol. 2017;24:2679-87; Zhu ZG, Kitayama J, Kim HH, Bok-Yan So J, et al. Asian consensus on normothermic intraperitoneal and systemic treatment for gastric cancer with peritoneal metastasis. Gastric Cancer. 2025;28:731-48.
5.Fujimoto S,Shrestha RD,Kokubun M,et al.Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding.Annals of Surgery.1988;208(1):36–41
6. Koga S, Hamazoe R, Maeta M, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer. 1988;61(1):232–237.
7. Fujimoto S, Shrestha RD, Kokubun M, et al. Clinical trial with surgery and intraperitoneal hyperthermic perfusion for peritoneal recurrence of gastrointestinal cancer. Cancer. 1989;64(1):154–158.
8. Yang J P, Lu Y, Zheng Z C, et al. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients with Peritoneal Carcinomatosis from Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial. Annals of Surgical Oncology. 2011;18(11):3126-3133.
9. Gao X, Yang S, Zhang B. Intraperitoneal Chemotherapy for Gastric Cancer with Peritoneal Carcinomatosis: Is HIPEC the Only Answer? World J Gastroenterol. 2014, 20(14):3829-3840.
10. Ji Jiafu, Bu Zhaode. The Evolution and Controversies of Intraperitoneal Hyperthermic Perfusion Chemotherapy for Peritoneal Metastasis from Gastric Cancer. Chinese Journal of Gastrointestinal Surgery. 2015;18(2):206–210.
11. Li Guoli, Wang Peng. Research progress in hyperthermic intraperitoneal chemotherapy for peritoneal metastasis of gastric cancer. Chinese Journal of Practical Surgery. 2015;35(7):798-802.
12. Moran B J. Then and now: cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (HIPEC), a historical perspective. Journal of Gastrointestinal Oncology. 2015;6(4):425-433.
13.Li G X, Liu J, Chen J, et al. Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with intraoperative detection of limited peritoneal metastasis: a Phase II study of the CLASS05 trial. Gastric Cancer. 2023;26(6):1125-1136
14. Rau B, Kroese A, Schmid S, et al. Survival stratification by peritoneal cancer index in gastric peritoneal carcinomatosis treated with cytoreductive surgery and HIPEC: a multicenter German registry study. World J Surg Oncol. 2022;20(1):247
15. Glehen O, Bonnot P E, Bereder J M, et al. Predictors of futile cytoreductive surgery plus HIPEC in gastric peritoneal carcinomatosis: a French multicenter cohort study. Eur J Surg Oncol. 2021;47(8):2024-2031.
16. Glehen O, et al. Cytoreductive surgery with or without HIPEC for gastric peritoneal carcinomatosis: the CYTO-CHIP randomized phase III trial. Ann Surg Oncol. 2020;27(13):5218-5226.
17.Acs M,Müller T,Mayr S,et al.Selection Criteria for Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy With Special Emphasis on Laparoscopy as an Efficient Tool.Anticancer Res.2022;42(6):3105-3112
18. Steinhoff H, Acs M, Blaj S, et al. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes of cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases. World J Gastroenterol. 2023;29(18):2850-2863.
19. Yu P F, Cheng X D, Chen Y B, et al. Neoadjuvant systemic and hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery for gastric cancer patients with limited peritoneal metastasis: a prospective cohort study. BMC Cancer. 2020;20(1):1108
20. Koenigsrainer A, et al. Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPECI Trial. Journal of Clinical Oncology. 2024;42(2):146-156.
21. Deraco M, Baratti D, Kusamura S, et al. Laparoscopic cytoreduction plus repeated postoperative HIPEC for peritoneal surface malignancies: standardized protocol and multicenter safety outcomes. European Journal of Surgical Oncology. 2022;48(7):1624-1631.
22. Kumamoto T, Ishigami S, Kitayama J, et al. Intraperitoneal paclitaxel plus systemic chemotherapy versus systemic chemotherapy alone for gastric cancer with peritoneal metastasis (PHOENIX-GC): a multicentre, open-label, randomised phase 3 trial. Lancet Gastroenterology & Hepatology. 2022;7(6):529-538.
23. Rau B, Lang H, Königsrainer A, et al. Effect of Hyperthermic Intraperitoneal Chemotherapy on Cytoreductive Surgery in Gastric Cancer With Synchronous Peritoneal Metastases: The Phase III GASTRIPECI Trial. Journal of Clinical Oncology. 2024;42(2):146-156.
24. European Society for Medical Oncology. Gastric cancer living clinical practice guidelines v1.4 (Sep 2024) [EB/OL]. ESMO, 2024
25.Ajani J A,D'Amico T A,Bentrem D J,et al.NCCN Clinical Practice Guidelines in Oncology:Gastric Cancer,Version 1.2026.JNCCN.2026;24(1):93-122
26.Terashima M,Li G X,Cheng X D,et al.PanAsian consensus statements on the management of gastric cancer with peritoneal metastasis.Gastric Cancer.2023;26(5):789-805
27. Glehen O, Bonnot P E, Bereder J M, et al. Predictors of futile cytoreductive surgery plus HIPEC in gastric peritoneal carcinomatosis: a French multicenter cohort study. Eur J Surg Oncol. 2021;47(8):2024-2031.
28. Zhang Z Z, Bai L, Xia X, et al. Combined detection of peritoneal lavage circulating tumor cells and peritoneal ctDNA predicts metachronous peritoneal metastasis and guides prophylactic hyperthermic intraperitoneal chemotherapy for gastric cancer. Translational Research. 2025;276:67-78.
29. Bai Long, Xia Xiang, Cao Hui, et al. Advances in the application of circulating tumor DNA in peritoneal lavage fluid for predicting peritoneal metastasis in gastrointestinal malignancies. Journal of Shanghai Jiao Tong University (Medical Science). 2023;43(12):1554-1560.
30. Beagan JJ, Sluiter NR, Bach S, et al. Circulating Tumor DNA as a Preoperative Marker of Recurrence in Patients with Peritoneal Metastases of Colorectal Cancer: A Clinical Feasibility Study. J Clin Med. 2020;9(6):1738
31. Li Y, Zhang Y, Wang C, et al. Intraperitoneal trastuzumab combined with HIPEC plus systemic trastuzumab chemotherapy for HER2-positive gastric cancer with peritoneal metastasis: a multicenter retrospective cohort study [J]. Journal of Surgical Oncology. 2025;130(2):398-406.
32. Cascinu S, Maccaroni E, Tiberio G, et al. Gene expression profile-guided personalized intraperitoneal chemotherapy for gastric cancer peritoneal carcinomatosis. European Journal of Surgical Oncology. 2024;50(7):1389-1396.
33. Rau B, Steinhoff H, Königsrainer A, et al. 60-minute versus 90-minute cisplatin-based hyperthermic intraperitoneal chemotherapy after complete cytoreduction for gastric peritoneal carcinomatosis: a European multicenter randomized phase II/III trial (GERM-HIPEC). British Journal of Surgery. 2025;112(7):892-902
34. Steinhoff H, Acs M, Blaj S, et al. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes of cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases. World J Gastroenterol. 2023;29(18):2850-2863.
35.Du Y,Ding G Y,Ye Z Y,et al.HIPEC combined with PD1 inhibitor,chemotherapy in conversion therapy for advanced gastric cancer with peritoneal metastasis:Results from a single-arm phase II clinical study.Journal of Clinical Oncology.2026;44(16_suppl):e16077
36. Xiang Z Y, Li S P, Yang X Y, et al. The clinical significance of hyperthermic intraperitoneal chemotherapy combined with PD-1 inhibitor and systemic chemotherapy for advanced gastric cancer patients with peritoneal metastasis. Frontiers in Oncology. 2025;15:1728724
37. Kang J, Li W. Hyperthermia enhances intraperitoneal PD1 efficacy against peritoneal micrometastases by reversing peritoneal immunosuppression. Cancer Immunology, Immunotherapy. 2024;73(8):1927-1938.
38. Zhang Y Z, Feng L. Efficacy and safety of HIPEC combined with PD-1 and SOX chemotherapy for gastric or oesophagogastric junctional cancer with peritoneal metastasis (HISTORIA): protocol for a prospective, multicentre, single-arm phase II trial. BMJ Open. 2025;15(8):e098326
39. Baratti D, Kusamura S, Deraco M. Matched-cohort comparison of pressurized aerosol intraperitoneal chemotherapy versus liquid intraperitoneal chemotherapy for non-resectable gastric peritoneal carcinomatosis. European Journal of Surgical Oncology. 2024;50(9):1762-1768.
40. Giannone F, Morabito A, Capri G, et al. Palliative versus bidirectional (downstaging-to-surgery) PIPAC strategy in unresectable peritoneal metastases: a comparative cohort study. BMC Cancer. 2025;25(1):729
41. Gastrointestinal Surgery Group, Surgical Society of the Chinese Medical Association. Chinese Expert Consensus on Palliative Local Treatment for Unresectable Peritoneal Metastatic Cancer (2026). Chinese Journal of Gastrointestinal Surgery. 2026;29(2):129–138.
42. van Sandick J W, Quik J S, van der Kaaij R T, et al. Overall survival of gastrectomy plus CRSHIPEC versus continued systemic therapy for gastric cancer with limited peritoneal metastases: the PERISCOPE II randomized phase 3 trial. Lancet Oncology. 2026;27(7):891-901.
43. Liang Han, Deng Jingyu, Cai Mingzhi, et al. Interim results of the HIPEC02 study: a multicenter randomized controlled trial of hyperthermic intraperitoneal chemotherapy combined with conversion chemotherapy for gastric cancer with limited peritoneal metastases. Chinese Journal of Clinical Oncology. 2024;51(6):289–296.
44. Gastrointestinal Surgery Group, Surgical Society of the Chinese Medical Association. Interpretation of the protocol for the multicenter, randomized, controlled trial of prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC01) following radical surgery for locally advanced gastric cancer. Chinese Journal of Gastrointestinal Surgery. 2026;29(3):241–246.
45. Goetze T, Piso P, Bankstahl U S, et al. Safety of preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: An interim safety analysis from the phase III PREVENT trial. Journal of Clinical Oncology. 2024;42(3_suppl):359
46. Lorenzen S, Al-Batran S E, PREVENT Study Group. Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma–the phase III “PREVENT” (FLOT9) study protocol. BMC Cancer. 2022;22(1):789.
47. Glehen O, Paye F, Elias D, et al. Study protocol of GASTRICHIP: a multicenter randomized phase III trial of adjuvant HIPEC after curative gastrectomy for locally advanced gastric cancer at high risk of peritoneal recurrence [NCT01882933]. BMC Cancer. 2019;19(1):420
48. Baron E, Xu Z S, Paro A, et al. Robotic versus open cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a propensity score-matched study. Surgical Endoscopy. 2026;40(3):1124-1132
49. Park J H, Lee S W. Comparative Sensing and Judgment Control System for Temperature Maintenance for Optimal Treatment in Hyperthermic Intraperitoneal Chemotherapy Surgery. Sensors. 2023;23(15):6789
50. Zhang L, Liang H. Machine learning model predicting survival benefit of CRS-HIPEC for gastric cancer with peritoneal metastasis based on PCI, blood routine and tumor markers. Gastric Cancer. 2026;29(4):712-723.
51. Baratti D, Kusamura S. CT radiomics-clinical machine-learning model to predict completeness of cytoreduction in colorectal peritoneal metastases. European Journal of Surgical Oncology. 2025;51(8):1687-1694
52. Glehen O, for ROBOCHIP Study Group. Robotic Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Gastric Peritoneal Metastasis: Phase II Interim Analysis [NCT05753306]. Annals of Surgical Oncology. 2026; 33(Suppl 1): S217
Key words:
Related News